Effect of an E-Prescription Intervention on the Adherence to Surgical Chemoprophylaxis Duration in Cardiac Surgery: A Single Centre Experience
Abstract
:1. Introduction
2. Results
2.1. Demographics and Comorbidities
2.2. Cardiac and Surgical History
2.3. Adherence to PAP Duration
2.4. Factors Associated with Adherence to Appropriate Duration
2.5. Individual Surgeon Adherence to PAP Duration
2.6. Adherence to Other Individual Elements of PAP
2.7. Secondary Outcomes of Antimicrobial Consumption
2.8. Other Secondary Outcomes
3. Discussion
4. Materials and Methods
4.1. Study Design and Patient Population
4.2. Intervention
4.3. Data Collection
4.4. Outcomes
4.5. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Brandao, S.M.G.; Hueb, W.; Ju, Y.T.; Lima, A.C.P.; Polanczyk, C.A.; Cruz, L.N.; Garcia, R.M.R.; Takiuti, M.E.; Bocchi, E.A. Utility and quality-adjusted life-years in coronary artery disease: Five-year follow-up of the MASS II trial. Medicine 2017, 96, e9113. [Google Scholar] [CrossRef] [PubMed]
- Wu, Y.; Jin, R.; Gao, G.; Grunkemeier, G.L.; Starr, A. Cost-effectiveness of aortic valve replacement in the elderly: An introductory study. J. Thorac. Cardiovasc. Surg. 2007, 133, 608–613. [Google Scholar] [CrossRef] [Green Version]
- Vieira, R.D.; Hueb, W.; Hlatky, M.; Favarato, D.; Rezende, P.C.; Garzillo, C.L.; Lima, E.G.; Soares, P.R.; Hueb, A.C.; Pereira, A.C.; et al. Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial. Circulation 2012, 126, S145–S150. [Google Scholar] [CrossRef] [Green Version]
- Zukowska, A.; Zukowski, M. Surgical Site Infection in Cardiac Surgery. J. Clin. Med. 2022, 11, 6991. [Google Scholar] [CrossRef]
- Gelijns, A.C.; Moskowitz, A.J.; Acker, M.A.; Argenziano, M.; Geller, N.L.; Puskas, J.D.; Perrault, L.P.; Smith, P.K.; Kron, I.L.; Michler, R.E.; et al. Management practices and major infections after cardiac surgery. J. Am. Coll. Cardiol. 2014, 64, 372–381. [Google Scholar] [CrossRef] [Green Version]
- Goh, S.S.C. Post-sternotomy mediastinitis in the modern era. J. Card. Surg. 2017, 32, 556–566. [Google Scholar] [CrossRef]
- Bratzler, D.W.; Dellinger, E.P.; Olsen, K.M.; Perl, T.M.; Auwaerter, P.G.; Bolon, M.K.; Fish, D.N.; Napolitano, L.M.; Sawyer, R.G.; Slain, D.; et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg. Infect. 2013, 14, 73–156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Edwards, F.H.; Engelman, R.M.; Houck, P.; Shahian, D.M.; Bridges, C.R.; Society of Thoracic, S. The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part I: Duration. Ann. Thorac. Surg. 2006, 81, 397–404. [Google Scholar] [CrossRef]
- Engelman, R.; Shahian, D.; Shemin, R.; Guy, T.S.; Bratzler, D.; Edwards, F.; Jacobs, M.; Fernando, H.; Bridges, C.; Workforce on Evidence-Based Medicine, S.o.T.S. The Society of Thoracic Surgeons practice guideline series: Antibiotic prophylaxis in cardiac surgery, part II: Antibiotic choice. Ann. Thorac. Surg. 2007, 83, 1569–1576. [Google Scholar] [CrossRef]
- Cove, M.E.; Spelman, D.W.; MacLaren, G. Infectious complications of cardiac surgery: A clinical review. J. Cardiothorac. Vasc. Anesth. 2012, 26, 1094–1100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lemaignen, A.; Birgand, G.; Ghodhbane, W.; Alkhoder, S.; Lolom, I.; Belorgey, S.; Lescure, F.X.; Armand-Lefevre, L.; Raffoul, R.; Dilly, M.P.; et al. Sternal wound infection after cardiac surgery: Incidence and risk factors according to clinical presentation. Clin. Microbiol. Infect. 2015, 21, 674.e11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sharif, M.; Wong, C.H.M.; Harky, A. Sternal Wound Infections, Risk Factors and Management-How Far Are We? A Literature Review. Heart Lung Circ. 2019, 28, 835–843. [Google Scholar] [CrossRef] [PubMed]
- Kreter, B.; Woods, M. Antibiotic prophylaxis for cardiothoracic operations. Meta-analysis of thirty years of clinical trials. J. Thorac. Cardiovasc. Surg. 1992, 104, 590–599. [Google Scholar] [CrossRef] [PubMed]
- Mertz, D.; Johnstone, J.; Loeb, M. Does duration of perioperative antibiotic prophylaxis matter in cardiac surgery? A systematic review and meta-analysis. Ann. Surg. 2011, 254, 48–54. [Google Scholar] [CrossRef]
- Hamouda, K.; Oezkur, M.; Sinha, B.; Hain, J.; Menkel, H.; Leistner, M.; Leyh, R.; Schimmer, C. Different duration strategies of perioperative antibiotic prophylaxis in adult patients undergoing cardiac surgery: An observational study. J. Cardiothorac. Surg. 2015, 10, 25. [Google Scholar] [CrossRef] [Green Version]
- Harbarth, S.; Samore, M.H.; Lichtenberg, D.; Carmeli, Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 2000, 101, 2916–2921. [Google Scholar] [CrossRef] [Green Version]
- Branch-Elliman, W.; O’Brien, W.; Strymish, J.; Itani, K.; Wyatt, C.; Gupta, K. Association of Duration and Type of Surgical Prophylaxis with Antimicrobial-Associated Adverse Events. JAMA Surg. 2019, 154, 590–598. [Google Scholar] [CrossRef]
- Dias, P.; Patel, A.; Rook, W.; Edwards, M.R.; Pearse, R.M.; Abbott, T.E.F.; Investigators, S. Contemporary use of antimicrobial prophylaxis for surgical patients: An observational cohort study. Eur. J. Anaesthesiol. 2022, 39, 533–539. [Google Scholar] [CrossRef]
- Ierano, C.; Thursky, K.; Marshall, C.; Koning, S.; James, R.; Johnson, S.; Imam, N.; Worth, L.J.; Peel, T. Appropriateness of Surgical Antimicrobial Prophylaxis Practices in Australia. JAMA Netw. Open. 2019, 2, e1915003. [Google Scholar] [CrossRef] [Green Version]
- Tiri, B.; Bruzzone, P.; Priante, G.; Sensi, E.; Costantini, M.; Vernelli, C.; Martella, L.A.; Francucci, M.; Andreani, P.; Mariottini, A.; et al. Impact of Antimicrobial Stewardship Interventions on Appropriateness of Surgical Antibiotic Prophylaxis: How to Improve. Antibiotics 2020, 9, 168. [Google Scholar] [CrossRef] [Green Version]
- Surat, G.; Bernsen, D.; Schimmer, C. Antimicrobial stewardship measures in cardiac surgery and its impact on surgical site infections. J. Cardiothorac. Surg. 2021, 16, 309. [Google Scholar] [CrossRef]
- Tourmousoglou, C.E.; Yiannakopoulou, E.; Kalapothaki, V.; Bramis, J.; St Papadopoulos, J. Adherence to guidelines for antibiotic prophylaxis in general surgery: A critical appraisal. J. Antimicrob. Chemother. 2008, 61, 214–218. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chorafa, E.; Iosifidis, E.; Tsiodras, S.; Skoutelis, A.; Kourkouni, E.; Kopsidas, I.; Tsopela, G.C.; Chorianopoulou, E.; Triantafyllou, C.; Kourlaba, G.; et al. Perioperative antimicrobial prophylaxis in adult patients: The first multicenter clinical practice audit with intervention in Greek surgical departments. Infect. Control Hosp. Epidemiol. 2021, 42, 702–709. [Google Scholar] [CrossRef] [PubMed]
- Bratzler, D.W.; Houck, P.M.; Richards, C.; Steele, L.; Dellinger, E.P.; Fry, D.E.; Wright, C.; Ma, A.; Carr, K.; Red, L. Use of antimicrobial prophylaxis for major surgery: Baseline results from the National Surgical Infection Prevention Project. Arch. Surg. 2005, 140, 174–182. [Google Scholar] [CrossRef] [Green Version]
- Puig-Asensio, M.; Perencevich, E.N.; Livorsi, D.J. Prolonged postprocedural antimicrobial use: A survey of the Society for Healthcare Epidemiology of America Research Network. Infect. Control Hosp. Epidemiol. 2019, 40, 1281–1283. [Google Scholar] [CrossRef]
- Cheng, H.; Chen, B.P.; Soleas, I.M.; Ferko, N.C.; Cameron, C.G.; Hinoul, P. Prolonged Operative Duration Increases Risk of Surgical Site Infections: A Systematic Review. Surg. Infect. 2017, 18, 722–735. [Google Scholar] [CrossRef] [Green Version]
- Global Guidelines for the Prevention of Surgical Site Infection. Web Appendix 25, Summary of a Systematic Review on Surgical Antibiotic Prophylaxis Prolongation. Available online: https://www.ncbi.nlm.nih.gov/books/NBK536429/ (accessed on 12 June 2023).
- Wade, T.; Roberts, N.; Ban, J.W.; Waweru-Siika, W.; Winston, H.; Williams, V.; Heneghan, C.J.; Onakpoya, I.J. Utility of healthcare-worker-targeted antimicrobial stewardship interventions in hospitals of low-and lower-middle-income countries: A scoping review of systematic reviews. J. Hosp. Infect. 2023, 131, 43–53. [Google Scholar] [CrossRef]
- European Centre for Disease Prevention and Control. Point Prevalence Survey of Healthcare-Associated infections and Antimicrobial Use in European Acute Care Hospitals, 2016–2017; European Centre for Disease Prevention and Control: Stockholm, Sweden, 2023. [Google Scholar]
- Plachouras, D.; Karki, T.; Hansen, S.; Hopkins, S.; Lyytikainen, O.; Moro, M.L.; Reilly, J.; Zarb, P.; Zingg, W.; Kinross, P.; et al. Antimicrobial use in European acute care hospitals: Results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017. Euro Surveill. 2018, 23, 1800393. [Google Scholar] [CrossRef] [Green Version]
- Monmaturapoj, T.; Scott, J.; Smith, P.; Watson, M.C. What influences the implementation and sustainability of antibiotic stewardship programmes in hospitals? A qualitative study of antibiotic pharmacists’ perspectives across South West England. Eur. J. Hosp. Pharm. 2022, 29, e46–e51. [Google Scholar] [CrossRef] [PubMed]
- Bouchet, F.; Le Moing, V.; Dirand, D.; Cros, F.; Lienard, A.; Reynes, J.; Giraudon, L.; Morquin, D. Effectiveness and Acceptance of Multimodal Antibiotic Stewardship Program: Considering Progressive Implementation and Complementary Strategies. Antibiotics 2020, 9, 848. [Google Scholar] [CrossRef] [PubMed]
- The NCEPOD Classification of Intervention. Available online: https://www.ncepod.org.uk/classification.html (accessed on 22 April 2023).
- ASA Physical Status Classification System. Available online: https://www.asahq.org/standards-and-guidelines/asa-physical-status-classification-system (accessed on 24 April 2023).
- Pittams, A.P.; Iddawela, S.; Zaidi, S.; Tyson, N.; Harky, A. Scoring Systems for Risk Stratification in Patients Undergoing Cardiac Surgery. J. Cardiothorac. Vasc. Anesth. 2022, 36, 1148–1156. [Google Scholar] [CrossRef] [PubMed]
- Emori, T.G.; Culver, D.H.; Horan, T.C.; Jarvis, W.R.; White, J.W.; Olson, D.R.; Banerjee, S.; Edwards, J.R.; Martone, W.J.; Gaynes, R.P.; et al. National nosocomial infections surveillance system (NNIS): Description of surveillance methods. Am. J. Infect. Control 1991, 19, 19–35. [Google Scholar] [CrossRef] [PubMed]
- Horan, T.C.; Andrus, M.; Dudeck, M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control 2008, 36, 309–332. [Google Scholar] [CrossRef] [PubMed]
- Cruz, M.; Pinto-Orellana, M.A.; Gillen, D.L.; Ombao, H.C. RITS: A toolbox for assessing complex interventions via interrupted time series models. BMC Med. Res. Methodol. 2021, 21, 143. [Google Scholar] [CrossRef] [PubMed]
Pre-Intervention, N (%) | Post-Intervention, N (%) | Total, N | p Value | |
---|---|---|---|---|
Gender (Male) | 290/400 (72.5%) | 517/680 (76.0%) | 807/1080 (74.7%) | 0.197 |
Mean Age (years, (SD) | 66.2 (10.7) | 65.7 (11.2) | 65.8 (11.0) | 0.53 |
ΒΜΙ ≥ 30 Kg/m2 | 65/1080 (16.5%) | 174/1080 (25.6%) | 239/1080 (22.3%) | 0.02 |
Mean BMI, Kg/m2 (SD) | 27.0 (3.9) | 27.5 (4.3) | 27.3 (4.2) | 0.083 |
History of smoking | 105/399 (26.3%) | 252/680 (37.1%) | 357/1079 (33.1%) | <0.001 |
Diabetes | 133/400 (33.3%) | 281/680 (41.3%) | 414/1080 (38.3%) | 0.008 |
Hypertension | 368/400 (92.0%) | 638/680 (93.8%) | 1006/1080 (93.1%) | 0.252 |
Dyslipidemia | 287/399 (71.9%) | 495/680 (72.8%) | 782/1079 (72.5%) | 0.759 |
Immunosuppression (therapy/disease) | 25/400 (6.3%) | 51/680 (7.5%) | 76/1080 (7.0%) | 0.438 |
Peripheral vascular disease | 42/400 (10.5%) | 68/679 (10.0%) | 110/1079 (10.2%) | 0.799 |
Chronic kidney disease (G3 or higher) | 123/400 (30.7%) | 157/680 (23.1%) | 280/1080 (25.1%) | 0.515 |
Chronic lung disease | 24/400 (6.0%) | 57/680 (8.4%) | 81/1080 (7.5%) | 0.151 |
History of Cerebrovascular disease | 12/400 (3.0%) | 34/680 (5.0%) | 46/1080 (4.3%) | 0.116 |
History of malignancy | 17/400 (4.3%) | 32/680 (4.7%) | 49/1080 (4.5% | 0.728 |
Thyroid disease | 35/400 (8.8%) | 70/679 (10.3%) | 105/1079 (9.7%) | 0.404 |
Other comorbidities | 85/400 (21.3%) | 185/680 (27.2%) | 270/1080 (25.0%) | 0.029 |
PAP Element | Pre-Intervention, N (%) | Post-Intervention, N (%) | p Value |
---|---|---|---|
Appropriate duration | |||
Appropriate duration 1st antibiotic | 19/399 (4.8%) | 116/680 (17.1%) | <0.001 |
Appropriate duration 2nd antibiotic | 59/375 (15.7%) | 163/659 (24.7%) | 0.001 |
Appropriate duration overall | 16/399 (4.0%) | 105/680 (15.4%) | <0.001 |
Appropriate duration overall—CABG only | 11/229 (4.8%) | 58/345 (16.8%) | <0.001 |
Appropriate duration overall—HVAR only | 2/109 (1.8%) | 34/216 (15.7%) | <0.001 |
Appropriate duration overall—Composite operation | 3/61 (4.9%) | 13/119 (10.9%) | 0.018 |
Appropriate choice | |||
Appropriate choice 1st antibiotic | 381/400 (95.3%) | 673/680 (99.0%) | <0.001 |
Appropriate choice 2nd antibiotic | 18/396 (4.5%) | 241/680 (35.4%) | <0.001 |
Appropriate choice of antibiotic overall | 16/400 (4.0%) | 238/680 (35.0%) | <0.001 |
Appropriate timing of initiation | |||
Appropriate timing 1st antibiotic | 396/400 (99.0%) | 679/680 (99.9%) | 0.046 |
Appropriate timing 2nd antibiotic | 350/400 (92.8%) | 625/680 (94.8%) | 0.19 (ns) |
Appropriate timing Overall | 373/400 (93.3%) | 645/680 (94.9%) | 0.27 (ns) |
Appropriate redosing | |||
Appropriate redosing 1st antibiotic | 0/4 (0%) | 0/6 (0%) | n/a |
Appropriate redosing 2nd antibiotic | 0/183(0%) | 0/194 (0%) | n/a |
(A) | ||||||||
Appropriate PAP Duration | ||||||||
Variable | Category | No (n, %) | Yes (n, %) | OR (95% CI) | p | |||
Phase of the study | PRE | 383 (96.0%) | 16 (4.0%) | |||||
POST | 575 (84.6%) | 105 (15.4%) | 4.37 (2.54–7.51) | <0.001 | ||||
Sex | Male | 710 (88.0%) | 97 (12.0%) | |||||
Female | 248 (91.2%) | 24 (8.8%) | 0.70 (0.44–1.13) | 0.149 | ||||
Age > 65 | >65 | 532 (89.4%) | 63 (10.6%) | |||||
≤65 | 426 (88.0%) | 58 (12.0%) | 0.87 (0.59–1.27) | 0.47 | ||||
BMI (cat) | Normal | 293 (89.3%) | 35 (10.7%) | |||||
Overweight | 444 (87.9%) | 61 (12.1%) | ||||||
Obese | 214 (89.5%) | 25 (10.5%) | n/a | 0.739 | ||||
Diabetes mellitus | Yes | 361 (87.2%) | 53 (12.8%) | |||||
No | 597 (89.8%) | 68 (10.2%) | 1.29 (0.88–1.89) | 0.192 | ||||
CKD | Yes | 26 (78.8%) | 7 (21.2%) | |||||
No | 932 (89.1%) | 114 (10.9%) | 2.20 (0.93–5.18) | 0.65 | ||||
COPD | Yes | 75 (92.6%) | 6 (7.4%) | |||||
No | 883 (88.5%) | 115 (11.5%) | 0.61 (0.262–1.44) | 0.259 | ||||
History of neoplasm | Yes | 40 (81.6%) | 9 (18.4%) | |||||
No | 918 (89.1%) | 112 (10.9%) | 1.84 (0.87–3.90) | 0.104 | ||||
Immunosuppression | Yes | 65 (85.5%) | 11 (14.5%) | |||||
No | 893 (89.0%) | 110 (11.0%) | 1.37 (0.70–2.68) | 0.35 | ||||
Permanent pacemaker (preop) | Yes | 29 (82.9%) | 6 (17.1%) | |||||
No | 929 (89.0%) | 115 (11.0%) | 1.67 (0.68–4.11) | 0.258 | ||||
History of prior cardiac surgery | Yes | 165 (89.7%) | 19 (10.3%) | |||||
No | 793 (88.6%) | 102 (11.4%) | 0.89 (0.53–1.50) | 0.675 | ||||
History of endocarditis | Yes | 27 (93.1%) | 2 (6.9%) | |||||
No | 930 (88.7%) | 119 (11.3%) | 0.58 (0.14–2.46) | 0.454 | ||||
Preoperative hospitalization ≥3 days | Yes | 400 (86.2%) | 64 (13.8%) | |||||
No | 558 (90.7%) | 57 (9.3%) | 1.56 (1.07–2.29) | 0.020 | ||||
Preoperative infection | Yes | 37 (88.1%) | 5 (11.9%) | |||||
No | 921 (88.8%) | 116 (11.2%) | 1.07 (0.41–2.78) | 0.885 | ||||
Preoperative CRP | >0.5 mg/dL | 294 (88.3%) | 39 (11.7%) | |||||
<0.5 mg/dL | 664 (89.0%) | 82 (11.0%) | 1.07 (0.72–1.61) | 0.729 | ||||
Preoperative WBC | Low | 43 (93.5%) | 3 (6.5%) | |||||
Normal | 822 (88.8%) | 104 (11.2%) | ||||||
High | 93 (86.9%) | 14 (13.1%) | n/a | 0.498 | ||||
Critical preoperative status | Yes | 23 (92.0%) | 2 (8.0%) | |||||
No | 933 (88.7%) | 119 (11.3%) | 0.68 (0.16–2.93) | 0.604 | ||||
Premature PAP initiation | Yes | 174 (94.1%) | 11 (5.9%) | |||||
No | 784 (87.7%) | 110 (12.3%) | 0.45 (0.24–0.86) | 0.013 | ||||
(B) | ||||||||
Appropriate PAP Duration | ||||||||
Variable | Category | No (n, %) | Yes (n, %) | p | ||||
Type of procedure | CABG only | 505 (88.0%) | 69 (12.0%) | |||||
HVAR only * | 261 (89.4%) | 31 (10.6%) | ||||||
Composite | 192 (90.1) | 21 (9.9%) | 0.646 | |||||
Surgical urgency | Immediate | 6 (100.0%) | 0 (0.0%) | |||||
Emergent | 10 (100.0%) | 0 (0.0%) | ||||||
Expedited | 272 (87.2%) | 40 (12.8%) | ||||||
Elective | 670 (89.2%) | 81 (10.8%) | 0.397 | |||||
ASA score | ΙΙ | 241 (90.9%) | 24 (9.1%) | |||||
ΙΙΙ | 479 (88.4%) | 63 (11.6%) | ||||||
IV | 237 (87.5%) | 34 (12.5%) | 0.404 | |||||
BASIC RISK INDEX | 0 | 4 (100.0%) | 1 (0.0%) | |||||
1 | 753 (87.7%) | 106 (12.3%) | ||||||
2 | 190 (93.6%) | 13 (6.4%) | ||||||
3 | 10 (83.3%) | 2 (16.7%) | 0.083 | |||||
EUROSCORE category | Low | 596 (89.0%) | 74 (11.0%) | |||||
Intermediate | 258 (86.6%) | 40 (13.4%) | ||||||
High | 91 (93.8%) | 6 (6.2%) | ||||||
Very high | 13 (92.9%) | 1 (7.1%) | 0.243 | |||||
CLEVELAND category | Low | 527 (88.6%) | 68 (11.4%) | |||||
Intermediate | 303 (88.9%) | 38 (11.1%) | ||||||
High | 127 (89.4%) | 15 (10.6%) | 0.956 | |||||
Surgeon | A | 158 (79.4%) | 41 (20.6%) | |||||
B | 57 (95.0%) | 3 (5.0%) | ||||||
C | 147 (87.5%) | 21 (12.5%) | ||||||
D | 339 (88.5%) | 44 (11.5%) | ||||||
E | 238 (96.4%) | 9 (3.6%) | <0.001 | |||||
Duration of operation ≤4 h | ≤4 h | 481 (83.9%) | 92 (16.1%) | |||||
>4 h | 474 (94.2%) | 29 (5.8%) | <0.001 |
Variable | Odds Ratio | Lower 95% C.I. | Upper 95% C.I. | p |
---|---|---|---|---|
Phase of the study | 4.708 | 2.545 | 8.71 | 0.000 |
Sex | 0.655 | 0.395 | 1.089 | 0.099 |
Diabetes mellitus | 1.224 | 0.807 | 1.855 | 0.303 |
History of endocarditis | 0.329 | 0.043 | 2.498 | 0.304 |
History of neoplasm | 1.992 | 0.689 | 5.757 | 0.171 |
Immunosuppression | 0.995 | 0.388 | 2.550 | 0.843 |
Permanent pacemaker (preop) | 2.097 | 0.791 | 5.559 | 0.127 |
Premature PAP initiation | 0.769 | 0.337 | 1.753 | 0.490 |
Prior cardiac surgery | 0.864 | 0.494 | 1.510 | 0.515 |
Preoperative infection | 2.373 | 0.530 | 10.618 | 0.283 |
Preoperative hospitalization ≥3 days | 1.874 | 1.235 | 2.843 | 0.003 |
Critical preoperative status | 0.799 | 0.164 | 3.890 | 0.693 |
Duration of operation >4 h (1) | 2.328 | 1.425 | 3.805 | 0.003 |
Surgeon | 0.001 | |||
Surgeon A * | 1.492 | 0.908 | 2.452 | 0.829 |
Surgeon B | 0.342 | 0.100 | 1.168 | 0.007 |
Surgeon C | 0.874 | 0.484 | 1.58 | 0.000 |
Surgeon E | 0.302 | 0.140 | 0.655 | 0.010 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kostourou, S.; Samiotis, I.; Dedeilias, P.; Charitos, C.; Papastamopoulos, V.; Mantas, D.; Psichogiou, M.; Samarkos, M. Effect of an E-Prescription Intervention on the Adherence to Surgical Chemoprophylaxis Duration in Cardiac Surgery: A Single Centre Experience. Antibiotics 2023, 12, 1182. https://doi.org/10.3390/antibiotics12071182
Kostourou S, Samiotis I, Dedeilias P, Charitos C, Papastamopoulos V, Mantas D, Psichogiou M, Samarkos M. Effect of an E-Prescription Intervention on the Adherence to Surgical Chemoprophylaxis Duration in Cardiac Surgery: A Single Centre Experience. Antibiotics. 2023; 12(7):1182. https://doi.org/10.3390/antibiotics12071182
Chicago/Turabian StyleKostourou, Sofia, Ilias Samiotis, Panagiotis Dedeilias, Christos Charitos, Vasileios Papastamopoulos, Dimitrios Mantas, Mina Psichogiou, and Michael Samarkos. 2023. "Effect of an E-Prescription Intervention on the Adherence to Surgical Chemoprophylaxis Duration in Cardiac Surgery: A Single Centre Experience" Antibiotics 12, no. 7: 1182. https://doi.org/10.3390/antibiotics12071182
APA StyleKostourou, S., Samiotis, I., Dedeilias, P., Charitos, C., Papastamopoulos, V., Mantas, D., Psichogiou, M., & Samarkos, M. (2023). Effect of an E-Prescription Intervention on the Adherence to Surgical Chemoprophylaxis Duration in Cardiac Surgery: A Single Centre Experience. Antibiotics, 12(7), 1182. https://doi.org/10.3390/antibiotics12071182